135 results about "Influenza a" patented technology

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

This invention provides an H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method, relating to the field of vaccine preparation technology. The H3N2 influenza mRNA vaccine is obtained by linking the conserved amino acid sequences of HA and NA of H3N2 with GGGSGGGSGGGSGGGS, and the amino acid sequence of the H3N2 influenza mRNA vaccine is shown in SEQ ID NO.1, and the nucleic acid sequence is shown in SEQ ID NO.2. This invention overcomes the shortcomings of existing technologies, improves the protective effect of the vaccine against H3N2 influenza, and enables it to better cope with immune evasion from the latest emerging H3N2 variants.

The invention discloses an influenza reporter virus carrying a fluorescent RNA aptamer and a construction method and application thereof, and the influenza reporter virus carrying the fluorescent RNA aptamer is obtained by introducing a termination codon TAA into the 328th nucleotide of an ORF region of an NS1 gene on the basis of a genome of an influenza A virus and terminating in advance, then introducing a terminating codon TAA into the 328th nucleotide of the ORF region of the NS1 gene of the influenza A virus; original nucleotides at the 328-480 sites are replaced by forward or reverse RNA aptamers, and the RNA aptamer is obtained. The influenza reporter virus carrying the fluorescent RNA aptamer constructed by the invention also has the characteristics of good virus replication ability, high RNA imaging sensitivity and good specificity on the basis of stable inheritance, can be used for real-time visual observation of virus RNA, and is used for research on virus replication cycle and molecular mechanism related to the virus RNA. Besides, the construction method of the influenza reporter virus carrying the fluorescent RNA aptamer can also be applied to construction of RNA fluorescent reporter viruses of other subtype influenza viruses such as H3N2 and H5N1, and an important tool is provided for real-time tracing of corresponding virus RNA.

The invention belongs to the field of new application of medicines, and particularly relates to application of 4-hydroxyderrisin in preparation of anti-influenza virus medicines. It is found for the first time that 4-hydroxyderrisin can significantly inhibit replication and internalization of influenza A virus H1N1 and has significant anti-influenza virus activity, the median inhibitory concentrations of 4-hydroxyderrisin in MDCK cells and A549 cells are 0.60 M and 0.23 M respectively, and the 4-hydroxyderrisin is low in cytotoxicity and high in safety. Experiments show that 4-hydroxyderrisin plays a role in the early stage of a virus life replication cycle, and plays an antiviral role by inhibiting virus internalization without affecting virus adsorption and neuraminidase activity. The medicine can be prepared into a solid or solution dosage form, is used for preventing and treating influenza, and has a good application prospect.

This invention discloses a method, system, and device for branching the gene sequence of influenza A virus, relating to the field of bioinformatics. The method includes the following steps: reading a user-input phylogenetic tree structure file and a Fasta file; dividing the phylogenetic tree into multiple branches based on a set first custom parameter and the gene sequence data of each cotyledon node; verifying the relationship between branches based on a set second custom parameter, and merging branches whose genetic distance is within a set threshold; verifying the merged branches; and if there are unassigned cotyledon nodes, assigning them to the branch with the closest genetic distance that satisfies the custom parameter, thereby obtaining the final branching result of the influenza A virus gene sequence. The method employed in this invention enables targeted phylogenetic branching based on the characteristics of influenza A virus, improving the accuracy of the branching results.

The present invention relates to the use of mesenchymal stem cells (MSCs) for enhancing the immune response of elderly or animal subjects to vaccination. According to the application, the defects of spleen stromal cell networks and lymphocyte structures of old subjects can be repaired by applying the MSC in advance, and the immune level of organisms is improved; and the vaccine is injected after a period of time, so that the specific antibody level after vaccine immunization can be improved. The effect can also significantly prevent the elderly subjects from being infected by influenza. Therefore, the MSC has a good application prospect in solving related immune decline of old people.

The application provides an influenza risk forecast method, device and equipment based on high-impact weather classification, and relates to the technical field of influenza risk forecast. The method comprises the following steps: acquiring weather forecast data of a future period, and determining future high-impact weather process information based on the weather forecast data of the future period; acquiring current high-impact weather process information and previous high-impact weather process information; determining a high-impact weather complexity intensity index according to the previous high-impact weather process information, the current high-impact weather process information and the future high-impact weather process information; and determining an influenza risk forecast level according to the high-impact weather complexity intensity index and a process type of the future high-impact weather process. The application constructs a forecast model based on the evolution law of the high-impact weather process, breaks through the limitation of meteorological element data, accurately associates the internal relationship between the weather change trend and the occurrence and spread of influenza, and forecasts more accurately.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.

Disclosed herein are cap-dependent endonuclease (CEN) inhibitors, compositions comprising them, and methods of their use to treat influenza.

The invention discloses respiratory tract infectious virus prevention and treatment equipment which comprises an oral cavity part, a throat part and a chest part, the oral cavity part comprises a spherical infrared radiation shell, an electric heating layer is attached to the inner layer of the spherical infrared radiation shell, and a holding tube communicated with the interior of a spherical cavity is fixedly installed at the lower end of the spherical infrared radiation shell; the present invention provides a device for preventing and treating new coronal influenza, influenza A, pandemic influenza and recently found respiratory infectious viruses such as HMPV.

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and / or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

The application discloses use of vocolotab in preparation of a preparation for preventing, treating, alleviating or inhibiting influenza virus proliferation, alone or in combination with other preparations. Vocolotab and the composition containing vocolotab are safe, can well inhibit influenza virus proliferation, and have application prospect in treating influenza.

This invention provides a fully human anti-H3N2 virus neutralizing antibody IAV-3 and its applications, belonging to the fields of microbiology and immunology. The amino acid sequence of the heavy chain variable region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:2; the amino acid sequence of the heavy chain constant region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:3, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO:4. The neutralizing antibody provided by this invention has the characteristics of high expression, fully human origin, and good stability, making it suitable for industrial production and possessing potential application value in responding to current and future influenza caused by the H3N2 virus.

The invention relates to a multi-antigen component PEI lipid delivery system and an anti-avian influenza virus multivalent vaccine comprising the same, belongs to the technical field of biological medicines, and provides a delivery system consisting of PEI, squalene, cholesterol and mPEG. The preparation method comprises the following steps of: constructing mRNA (messenger ribonucleic acid) molecules and a composite vaccine antigen system consisting of prokaryotic expression purified H7N9 avian influenza NP antigen, loading the composite vaccine antigen system into a delivery system to obtain the nanoparticles with a virus-like structure, and displaying the HA protein antigen and the NP antigen in the structure of the nanoparticles in a particle form by the nanoparticles, so that the nanoparticles can be used for preparing the H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza virus. And the mRNA molecule for coding the NA antigen, which is combined with the mRNA molecule, can be delivered into a cell in a manner of fusing lipid and a cell membrane, so that the mRNA molecule can be effectively expressed to induce a body to generate specific antibody reactions aiming at HA, NA and NP, and the body can also generate specific CTL reactions aiming at HA, NA and NP of different influenza virus strain subtypes.

The present application belongs to the field of biotechnology, and particularly relates to different characteristics of a first inhibitor, a second inhibitor and a third inhibitor in coping with human influenza virus replication and avian influenza virus replication. The present application finds that the inhibitors can have the functions of inhibiting or promoting human influenza and / or avian influenza through research, and the efficacy of the inhibitors can be judged by researching the trend of the functions and the tissue half quantity of infection, thereby providing strong support for subsequent development of drugs reducing drug resistance, experiments and development of human / avian influenza drugs. Meanwhile, the present application also provides a model obtained from the screening result of the present application.

An RSV virus-like particle which includes a chimeric protein that includes a core consisting of an influenza M1 protein, an RSV-derived preF protein, an RSV-derived G protein or part of G protein displayed on the surface of the core, can exhibit excellent effects in terms of inhibiting RSV virus infection and inhibiting the inflammatory response of the lungs.

The invention discloses application of nicotinamide ribose (NR) in preparation of anti-influenza virus products, and belongs to the technical field of biotechnology and medicine. The NR is used as a human endogenous metabolite, has excellent safety, activates SIRT1 by increasing the NAD + level in cells, and further inhibits influenza virus NP protein nucleus input and virus RNA synthesis. Experiments prove that NR has a remarkable inhibition effect on replication of various subtype influenza A viruses such as H1N1, H9N2 and H3N2, still has an inhibition effect under high-MOI infection, has a good use effect at the early stage of infection, and provides a new choice for anti-influenza virus drugs.

The present invention provides immunogenic compositions comprising a secreted fusion protein, wherein the secreted fusion protein comprises a soluble influenza or rabies virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against influenza or rabies infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment, and / or diagnosis, and related kits.

The present invention provides vaccine compositions, methods and uses thereof, the vaccine compositions are immunogenic compositions of secreted fusion proteins, wherein the secreted fusion proteins comprise a rabies or soluble influenza virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against rabies or influenza infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment and / or diagnosis and related kits.

This invention belongs to the field of virus detection technology and discloses a digital PCR kit for the simultaneous detection of African horse sickness virus (ESV), West Nile virus (WNVI), and equine influenza H3N8. The kit includes primers and probes as shown in SEQ ID NO.1 to SEQ ID NO.21. After testing single-particle systems of the ESV-VP7 gene, ESV-NS2 gene, WNVI-NS5 gene, WNVI-NS2a gene, equine influenza H3N8-HA gene, and equine influenza H3N8-NA gene, a seven-particle digital PCR system including an internal standard was established. After testing linearity, specificity, limit of detection, repeatability, and comparison of single-particle and multiplex digital PCR systems, the developed digital PCR multiplex detection kit fully meets the development requirements, exhibiting high specificity and sensitivity, with limits of detection all below 10 copies / μL.

Disclosed are novel vaccine compositions comprising modulated Transferrin Binding Protein B (TbpB) polypeptides or immunogenic portions thereof. Notably, the TbpB polypeptides are modulated with respect to domains known as loop domains located in the C-terminal lobe of TbpB polypeptides. The vaccine compositions may be used to ameliorate, treat or prevent pathogenic infections in humans caused by pathogenic H. influenzae strains. Related methods and uses are also disclosed.

The invention discloses a composite water-soluble vaccine adjuvant and a preparation method thereof, and belongs to the technical field of biological medicines. The adjuvant is based on a composite technology of a water-soluble component and a targeted delivery carrier, through a dual targeting effect of mannose modified beta-glucan, the uptake efficiency of dendritic cells on antigens is remarkably improved, and regulation and control on immune response are realized in cooperation with levamisole. The adjuvant has the characteristics of uniform particle size, excellent water solubility, good storage stability and the like, the immunological enhancement effect of the adjuvant is remarkably superior to that of a traditional adjuvant, and the adjuvant can be widely applied to research and development of vaccines for influenza, tuberculosis, tumor and the like, and has important clinical value and industrialization potential.

The invention discloses a non-human animal integrated with a double-derived VH subclass fusion gene as well as a construction method and application of the non-human animal. The method comprises the following steps: firstly, constructing a gene construct containing human IGHV1-69 and IGHV3-23 fragments, a specific spacer region, a functional element and a rat heavy chain 3'enhancer, and microinjecting the gene construct into a C57BL / 6J fertilized egg with an endogenous heavy chain and a kappa light chain knocked out to obtain a transgenic mouse; through identification, after a mouse endogenous antibody is inactivated, a human gene is stably integrated, a human IgM antibody is expressed and H5N1 HA immunization is carried out, the use frequency of IGHV1-69 is remarkably increased, the mouse produces a high-titer specific antibody, and serum has neutralizing activity. The mouse can generate a target bnAbs aiming at the HA stem and the RBS in parallel, so that the antibody screening efficiency is improved, and an in-vivo screening and evaluation platform for simulating human body fluid response is provided for research and development of influenza antibodies and vaccines.